Friday, March 27, 2026

Ai Defense Stocks Trading March 27th

Ai Defense Stocks Trading March 27th

 

Stocks Mentioned: (Nasdaq: $VWAV), (NASDAQ: $PLTR), (NASDAQ: $DRS), (NASDAQ: $RKLB), (NASDAQ: $RCAT)

 



 

Investorideas.com, a  top 100 rated investment site for retail Investors following AI and defense stocks, reports on trading and news for  March 27th.

According to Grandview Research,” The global AI in aerospace and defense market size was valued at USD 22.45 billion in 2023 and is projected to reach USD 43.02 billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. AI-driven systems analyze data from various sources to optimize maintenance schedules, manage supply chains, and improve logistics. “

Palantir Technologies (NASDAQ: PLTR): Considered a leader in AI-driven defense software, PLTR has continued to experience high demand, with shares recently jumping over 10% following positive reports. The stock is trading down today, currently at 145.53

-2.03 (-1.38%) .

 

VisionWave Holdings, Inc (Nasdaq: VWAV)  is trading up  on news ,currently at 6.88

+0.30 (+4.64%), w ith a day’s high of $7.10. VisionWave is one of the few stocks in the sector that has managed to maintain gains in today’s session.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/03272-ai-defense-stocks-trading-vwav-palantir-rklb-rcat.asp

 

VisionWave Holdings, announced the completion of an internal research paper evaluating conceptual RF-based subsurface sensing architectures. The study, linked to the Company’s recent offshore energy engagement in Liberia, explores advanced RF technologies for improved subsurface mapping in energy and infrastructure applications. The concepts remain in the research stage with no assurance of commercial development.

 

Full news https://www.investorideas.com/CO/VWAV/news/2026/03271-visionwave-vwav-rf-subsurface-sensing-liberia-energy.asp

 

Leonardo DRS, Inc. (NASDAQ: DRS):  trading at 45.89 -0.64 (-1.38%), this company focuses on AI-enabled computing and sensing for military platforms. It recently hit a 92 Relative Strength Rating, indicating strong technical momentum. The stock had a morning high as of this report of $46.82.

 

Rocket Lab Corp (NASDAQ: RKLB): Gained on investor rotation into companies with AI-enabled national security programs, trading near all-time highs. The stock is trading at 62.10 -3.85 (-5.83%) as  of this report.

 

Red Cat Holdings (NASDAQ: RCAT): Noted for high performance with a 76.54% year-to-date return, focusing on AI-enabled drones. The stock is trading down asn the market pulls back today, currently at 13.18 -0.82 (-5.89%).


VisionWave Holdings is a Featured AI defense stock on Investorideaas.com 
https://www.investorideas.com/CO/VWAV/




Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp




Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy. 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 


VisionWave Holdings Inc. (Nasdaq: $VWAV) Unveils Internal Research on Next-Gen RF Subsurface Sensing Architectures in Support of Liberia Energy Initiative; @VWAVInc

VisionWave Holdings Inc. (Nasdaq: $VWAV) Unveils Internal Research on Next-Gen RF Subsurface Sensing Architectures in Support of Liberia Energy Initiative; @VWAVInc





Investorideas.com, a  top 100 rated investment site for retail Investors following AI and defense stocks, reports on breaking news for VisionWave Holdings, Inc (Nasdaq: VWAV), focused on advanced sensing, autonomy, and AI-driven systems for defense and security applications.

AI News summary:

VisionWave Holdings, Inc. (NASDAQ: VWAV) announced the completion of an internal research paper evaluating conceptual RF-based subsurface sensing architectures. The study, linked to the Company’s recent offshore energy engagement in Liberia, explores advanced RF technologies for improved subsurface mapping in energy and infrastructure applications. The concepts remain in the research stage with no assurance of commercial development.

VisionWave Holdings is a Featured AI defense stock on Investorideaas.com https://www.investorideas.com/CO/VWAV/

Company news release:

VisionWave Holdings, Inc (Nasdaq: VWAV) today announced the completion of an internal research paper evaluating conceptual radio-frequency (RF)–based subsurface sensing architectures which the Company intends to incorporate into its its broader long-term strategy in energy, infrastructure intelligence, and subsurface mapping.

This research initiative follows VisionWave’s recently announced strategic engagement in offshore energy exploration in Liberia and reflects the Company’s continued focus on exploring advanced sensing approaches designed to enhance situational awareness in complex environments. The research paper represents a technical evaluation and conceptual framework only, and not an existing commercial product or deployed system.  The Company emphasizes that the research paper represents a technical evaluation and conceptual framework, and not an existing commercial product or deployed system.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/03271-visionwave-vwav-rf-subsurface-sensing-liberia-energy.asp

The research paper, developed as part of the Company’s ongoing research and development efforts, examines the feasibility and architectural considerations of near-source RF sensing systems intended to provide enhanced subsurface visibility in select geological conditions. The work outlines a potential framework combining advanced antenna design, edge-based signal processing, and physics-informed computational models.

VisionWave believes that, if successfully developed and validated, such approaches may support improved detection of subsurface features, including geological boundaries, fracture networks, and other structural characteristics relevant to energy exploration and infrastructure applications. However, the Company notes that the concepts described in the research paper remain subject to significant technical validation, environmental dependencies, and engineering development.

Technology Overview

VisionWave’s research paper outlines a conceptual subsurface sensing architecture based on the integration of radio-frequency (RF) signal propagation, advanced antenna systems, and real-time computational processing.

Unlike conventional approaches that primarily measure formation properties surrounding the drill path, the proposed architecture is designed to analyze electromagnetic responses in the volume ahead of the sensing source. This is achieved through a combination of directional RF transmission, multi-element receiver arrays, and adaptive signal processing techniques intended to distinguish between direct-path signals, environmental interference, and formation-dependent responses.

The conceptual system architecture incorporates embedded processing capabilities at the edge, where acquired RF data may be conditioned, filtered, and interpreted in real time. This includes the use of model-based inversion techniques and physics-informed computational methods designed to translate complex electromagnetic responses into structured representations of subsurface characteristics.

The research paper further evaluates antenna configurations integrated within mechanically robust structures capable of operating in high-pressure and high-temperature environments. Particular emphasis is placed on managing signal distortion caused by surrounding structures and environmental conditions, while maintaining directional sensitivity and operational stability.

VisionWave’s research also explores hybrid computational frameworks combining classical electromagnetic modeling with machine learning–assisted interpretation. These methods are intended to improve signal discrimination and enable probabilistic interpretation of subsurface features under varying environmental conditions.

The Company reiterates that the technologies described in the research paper are conceptual in nature and remain under evaluation, with no assurance of successful development or commercial implementation.

The Company reiterates that the technologies described in the research paper are conceptual in nature and remain under evaluation, with no assurance of successful development or commercial implementation.

Integration with Conventional Drilling Systems

From a technical perspective, the research paper evaluates an approach designed to integrate RF-based sensing elements, including transmission components and antenna structures, into near-source sections of conventional drilling assemblies, in proximity to the drill bit.

This conceptual integration approach is intended to preserve traditional drilling workflows while introducing an additional sensing layer capable of capturing and interpreting electromagnetic responses during operation. By embedding sensing components within structurally compatible sections of the drilling system, the proposed architecture seeks to operate alongside conventional mechanical and geological processes without altering their core function.

The research paper emphasizes compatibility with established drilling environments, where mechanical integrity, durability, and operational continuity are critical. The concept focuses on maintaining the performance of conventional systems while augmenting them with additional data acquisition and interpretation capabilities.

VisionWave’s research strategy is based on the principle of incremental enhancement—evaluating advanced sensing and computational technologies as an additional layer of intelligence, rather than a replacement for existing methodologies. The Company believes such an approach may support practical adoption pathways, subject to successful technical validation.

The Company notes that any potential integration of such technologies would require extensive engineering development, validation, and field testing.  There can be no assurance that any such integration will occur or that the concepts will prove technically or commercially viable.

Management Commentary

“We are approaching subsurface exploration as a sensing and intelligence challenge rather than a purely mechanical process,” said Douglas Davis, Executive Chairman and Chief Executive Officer of VisionWave. “This research paper reflects our effort to evaluate how physics-based signal propagation and real-time computational methods may, over time, contribute to improved visibility in complex subsurface environments. Importantly, our approach is focused on augmenting existing systems with additional layers of intelligence, not replacing them. While still at a research and evaluation stage, we believe this direction represents a meaningful long-term opportunity to enhance how subsurface environments are understood.”

The Company views this research initiative as part of a broader strategy to expand its capabilities across multiple domains, including defense, infrastructure monitoring, and energy-related applications, where advanced sensing and real-time data interpretation may provide operational advantages.  Any expansion into energy-related applications remains highly speculative and subject to the substantial risks outlined below and in the Company’s SEC filings.

VisionWave will continue to evaluate and refine these concepts as part of its long-term research and development roadmap. There can be no assurance that the technologies described in the research paper will be successfully developed, validated, or commercialized.

About VisionWave Holdings Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a dual-market autonomous systems platform company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and sea.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the Letter of Engagement with the National Oil Company of Liberia (“NOCAL”), the potential pathway toward a Production Sharing Contract (“PSC”) for offshore Blocks LB-4 and LB-5, the possible deployment and performance of the Company’s proprietary RF-based sensing technologies in offshore petroleum exploration, anticipated strategic benefits from diversification into the global energy sector, expected financial commitments (including signing bonuses, data licensing fees, and signature bonuses), potential extensions of exclusivity, farm-out or partnering arrangements, and the Company’s broader strategy of applying defense-derived technologies to new industries. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.

Forward-looking statements are generally identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," and similar expressions, or by statements that events or trends "may," "will," or "could" occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to: the highly conditional and preliminary nature of the LOE, which does not grant petroleum rights and provides no assurance of PSC execution; failure to obtain prequalification from the Liberia Petroleum Regulatory Authority, regulatory approvals, or legislative ratification by the Liberian Legislature; delays or denials in the PSC process or LOE extension; technical, operational, or economic challenges in validating and deploying the Company’s RF-based sensing technologies in offshore exploration environments (a new application domain outside the Company’s primary defense and homeland security markets); the Company’s ability to fund material upfront commitments (including a $600,000 initial signing bonus and potential post-PSC data licensing and signature bonuses totaling millions of dollars) without significant dilution, debt, or partnering arrangements; geopolitical, political, regulatory, corruption, sanctions, or force majeure risks associated with operations or investments in Liberia or similar emerging markets; potential revocation of the LOE due to default, breach, or other events; inability to secure qualified strategic partners for farm-out or risk-sharing; adverse changes in global energy markets, commodity prices, or exploration economics; competition from established oil and gas operators with conventional seismic methods; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission, including those related to liquidity, capital resources, technology development, international expansion, and diversification risks. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company's SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

VWAV - Investor Contact: investors@vwav.inc

Website: https://www.vwav.inc



Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp




Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy. 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 


Tuesday, March 24, 2026

Novel Immunotherapeutics Stocks in the News (Nasdaq:$AEMD), (Nasdaq: $HURA), (NYSE: $AZN), (Nasdaq: $ELTX)

Novel Immunotherapeutics Stocks in the News (Nasdaq:$AEMD), (Nasdaq: $HURA), (NYSE: $AZN), (Nasdaq: $ELTX)

 

Novel immunotherapeutics Transforming Oncology

 



 



 

 

Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (Nasdaq:AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications.

 

Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.

 

The novel immunotherapeutics market is experiencing rapid growth, valued at approximately USD 150-168 billion in 2025 and projected to exceed USD 300 billion by 2033–2035.

 

Developing a Novel Immunotherapeutic Device to combat cancer and life-threatening viral Infections, Aethlon Medical, Inc. (Nasdaq:AEMD) just announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial, AEMD-2022-06, has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that “no safety concerns were noted with Hemopurifier device/procedure.”

 

Paid News Dissemination of behalf of AEMD

 

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03242-immunotherapeutics-oncology-aemd-hura-azn-eltx.asp

 

From the news:

The trial, titled “Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab”, is being conducted to assess the Hemopurifier’s safety, feasibility, and optimal dosing.

 

The DSMB- comprised of independent medical experts in nephrology and oncology- reviewed data from participants enrolled in the second cohort, in which patients received two Hemopurifier treatments over a one-week period.  Based on their evaluation, the DSMB found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) related to the Hemopurifier device or treatment have been reported.

 

"The DSMB's continued positive recommendation supports the safety profile observed to date and allows us to advance into the third and final cohort of this study,” said Steven LaRosa, M.D, Chief Medical Officer of Aethlon Medical. "We are encouraged by the gathering momentum of the trial and having a final data set and clinical study report to share with potential investors, partners and regulatory agencies.”

 

Enrollment for Cohort 3 is now open. In this final cohort, participants will receive three Hemopurifier treatments over a one-week period further evaluating safety, feasibility and dosing parameters at the study’s three active clinical sites in Australia. This trial is designed to enroll approximately 9 to 18-patients with solid tumors who have stable or progressive disease, while receiving treatment that includes Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®). 

 

The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of Hemopurifier- treated patients. In addition to safety monitoring, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of extracellular vesicles (EVs) and if these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These findings are expected to inform the design of a future efficacy and safety, Premarket Approval (PMA), study required by regulatory authorities.

 

Aethlon Medical, Inc. remains committed to advancing the Hemopurifier for use in oncology and will continue to provide updates as the clinical trial progresses.

 

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

 

TuHURA Biosciences, Inc. (NASDAQ:HURA), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, just announced Dr. Craig L. Tendler will provide strategic, operational and other related services consistent with those of a Chief Medical Officer (CMO). He will also continue with his current role as a member of the Board of Directors. Dr. Tendler will work with the Company to oversee clinical development strategy and operations of the company's pipeline, including its VISTA inhibiting antibody, TBS-2025.

 

From the news:

"Craig has been an active and valued member of our Board and enthusiastically agreed to provide strategic, operational and other related services consistent with those of a CMO. His decades of clinical and regulatory experience in accelerating drug development across therapeutic areas, notably in hematologic malignancies, will be of particular value to our TBS-2025 program," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "I am confident that his recent leadership role and strategic contributions to JNJ's menin inhibitor, bleximenib in NPM1 mutated AML, will prove invaluable to our regulatory pathway and development of TBS-2025 in AML and other blood related cancers. I look forward to working with Craig as we unlock the value in VISTA and other clinical programs."

 

Dr. Craig Tendler added, "I am excited about the potential benefits of TBS-2025 for blood- related cancers where the negative checkpoint, VISTA, has been implicated in playing a critical immunosuppressive role in both therapy failure and poor overall survival in AML, particularly in the molecularly defined subset of NPM1 mutated AML. We have already received preliminary feedback from the Division of Hematologic Malignancies I of the FDA on the early development plan and will continue to work closely  with the Agency to accelerate the clinical development of TBS-2025, both as monotherapy and in combination with menin inhibitors, an area where I have substantial experience."

 

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

 

On March 16th,  AstraZeneca  (NYSE: AZN) reported that Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the European Union (EU) for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The regimen includes two cycles of Imfinzi in combination with chemotherapy before and after surgery, followed by Imfinzi monotherapy.

 

From the news:

The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on the positive results from the MATTERHORN Phase III trial, which were published in The New England Journal of Medicine.

 

Gastric cancer is the fifth leading cause of cancer death globally, with nearly one million people diagnosed each year. In 2024, there were roughly 15,500 drug-treated patients in the EU with early-stage and locally advanced gastric or GEJ cancer.

 

Josep Tabernero, MD, PhD, head of the Medical Oncology Department at Vall d'Hebron University Hospital and director of the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, and principal investigator in the trial, said: “Despite curative-intent surgery and chemotherapy, patients with resectable gastric and gastroesophageal cancers still face high recurrence rates and an urgent need for improved long-term survival. In MATTERHORN, nearly 70 per cent of patients were still alive three years after treatment with the durvalumab-based perioperative regimen. This EU approval brings patients the first immunotherapy regimen to extend survival in this early setting and is poised to become the new standard of care.”

 

Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit, AstraZeneca, said: “This approval marks our third perioperative approval in Europe for an Imfinzi-based regimen, underscoring AstraZeneca’s commitment to transforming outcomes in early-stage disease, where cure is possible. For patients with early gastric and gastroesophageal cancers, this immunotherapy-based regimen delivers a durable survival benefit that increases over time.”

 

In a planned interim analysis, patients treated with the Imfinzi-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone (based on an event-free survival [EFS] hazard ratio [HR] of 0.71; 95% confidence interval [CI] 0.58–0.86; p<0.001). Estimated median EFS was not yet reached for the Imfinzi arm versus 32.8 months for the comparator arm. An estimated 78.2% of patients treated with the Imfinzi-based perioperative regimen were event-free at one year, compared to 74.0% in the comparator arm; the estimated 24-month EFS rate was 67.4% versus 58.5%, respectively.

 

In the final overall survival (OS) analysis, results showed the Imfinzi and FLOT perioperative regimen demonstrated a statistically significant and clinically meaningful survival improvement, reducing the risk of death by 22% compared to chemotherapy alone (based on a HR of 0.78; 95% CI 0.63-0.96; p=0.021). An estimated 69% of patients treated with the Imfinzi-based regimen were alive at three years compared with 62% in the comparator arm. At each subsequent prespecified OS landmark, the survival curves indicated increasing separation, signaling a greater magnitude of benefit over time for the Imfinzi-based regimen. An OS benefit was observed regardless of tumour PD-L1 status. OS results from MATTERHORN were presented in a Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2025.

 

Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, recently reported financial results for the year ended December 31, 2025 and provided recent corporate and clinical updates.

 

“In 2025, we made meaningful progress advancing ELI-002 7P in KRAS-mutant pancreatic cancer,” said Robert Connelly, Chief Executive Officer of Elicio. “We remain focused on completing the Phase 2 AMPLIFY-7P trial and reaching the event-driven primary DFS analysis expected in 1H 2026. We are encouraged by the continued observation of fewer disease progressions and deaths to date than projected in the 2:1 randomized trial, as well as by the durability of T-cell responses and clinical observations reported to date, which reinforce our confidence in ELI-002 7P’s potential to favorably impact outcomes. With capital expected to carry us beyond the anticipated DFS readout, we believe we are well positioned to deliver this important milestone and continue advancing our Amphiphile (“AMP”) platform in KRAS-mutant PDAC. We remain highly interested in the potential to expand the development of ELI-002 7P to neoadjuvant and metastatic PDAC and other KRAS+ tumors, with the goal of creating meaningful long-term value for patients and shareholders.”

 

Revolutionizing cancer treatment, novel immunotherapeutics are evolving as AI enters the sector. The market is also rapidly evolving with high-growth areas like CAR T-cell therapy, which is expected to see massive expansion.

 


Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured medical tech stock on Investorideas.com

https://www.investorideas.com/CO/AEMD/

 







About Investorideas.com – Where you find the best investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411


Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

 



 



 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device  for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review  of  the second cohort participant data and recommended advancing to the third and final cohort. They also stated that “no safety concerns were noted with Hemopurifier device/procedure”.

 

The trial, titled “Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors Who Have Stable or Progressive Disease While on a Treatment That Includes Pembrolizumab or Nivolumab”, is being conducted to assess the Hemopurifier’s safety, feasibility, and optimal dosing.

 

The DSMB- comprised of independent medical experts in nephrology and oncology- reviewed data from participants enrolled in the second cohort, in which patients received two Hemopurifier treatments over a one-week period.  Based on their evaluation, the DSMB found no safety concerns and confirmed that the Hemopurifier continues to demonstrate a favorable safety and tolerability profile. To date, no serious adverse events (SAEs) or Dose-Limiting Toxicities (DLTs) related to the Hemopurifier device or treatment have been reported.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03241-aethlon-medical-aemd-oncology-trial-final-cohort.asp

"The DSMB's continued positive recommendation supports the safety profile observed to date and allows us to advance into the third and final cohort of this study,” said Steven LaRosa, M.D, Chief Medical Officer of Aethlon Medical. "We are encouraged by the gathering momentum of the trial and having a final data set and clinical study report to share with potential investors, partners and regulatory agencies”.

 

Enrollment for Cohort 3 is now open. In this final cohort, participants will receive three Hemopurifier treatments over a one-week period further evaluating safety, feasibility and dosing parameters at the study’s three active clinical sites in Australia. This trial is designed to enroll approximately 9 to 18-patients with solid tumors who have stable or progressive disease, while receiving treatment that includes Pembrolizumab (Keytruda®) or Nivolumab (Opdivo®).

 

The primary endpoint of this trial is the incidence of adverse events and clinically significant changes in safety laboratory tests of Hemopurifier- treated patients. In addition to safety monitoring, the study is designed to examine the number of Hemopurifier treatments needed to decrease the concentration of extracellular vesicles (EVs) and if these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These findings are expected to inform the design of a future efficacy and safety, Premarket Approval (PMA), study required by regulatory authorities.

 

Aethlon Medical, Inc. remains committed to advancing the Hemopurifier for use in oncology and will continue to provide updates as the clinical trial progresses.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both vitro studies and human subjects.

 

The Hemopurifier holds a U.S. Food and Drug Breakthrough Device for:

·         The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and

·         The treatment of life-threatening viruses not addressed with approved therapies.

 

The Hemopurifier is being developed under an open Investigational Device Exemption (IDE) for both indications.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids. For more information visit www.AethlonMedical.com and follow the company on LinkedIn.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this press release  include but are not limited to statements regarding advancement and completion of the Company’s clinical trial; patient enrollment and timing; the safety, tolerability and dosing of the Hemopurifier; the potential biological or clinical effects of the Hemopurifier; the ability of the study to inform future trials; and the Company’s development plans, regulatory pathway and potential applications of the Hemopurifier. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitationthe number of patients who receive pembrolizumab or nivolumab that will have lasting clinical responses to these agentsdevice deficiencies or immediate complications; the possibility of novel treatment strategies; how the Hemopurifier may reduce tumor-derived extracellular vesicles and enhance T cell activity against tumors; the efficacy of continued clinical trials; development under IDE for indications; and/or the number of patients enrolled in each cohort. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances. The findings described herein are preliminary in nature, have not been peer-reviewed, and may not be replicated in subsequent studies or clinical trials.

 

Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all

 



Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

 

 


Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp